NIH's Psychedelic and Ketamine Trials Network Shrank to $12 Million and Moved to January 5

The federal government has spent most of 2026 talking about psychedelic medicine. In April an executive order directed ARPA-H money toward state psychedelic research programs and told FDA to fast-track breakthrough-designated compounds. In April FDA handed out priority vouchers to psilocybin. On November 9 Compass Pathways finished its rolling new drug application for COMP360 psilocybin in treatment-resistant depression.

On November 12 the National Institutes of Health posted the funding opportunity that asks the question none of that answers: if these drugs reach the clinic, how should an ordinary emergency department, VA clinic, or community mental health center actually use them?

That opportunity is RFA-MH-27-150, "Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)", a UM1 cooperative agreement from the National Institute of Mental Health with the National Institute on Drug Abuse as a partner. It funds a single national clinical trials network, the RAPIDs-CTN, built around a Data Coordinating Center and a set of federated clinical sites. And the final version is noticeably different from the forecast NIH published in September.

What Changed Between the Forecast and the NOFO

When NIH forecast this program in September, the listing showed $20 million for three awards and a November 13 due date. We covered that forecast at the time in Granted News. Applicants who planned around it need to reset three things.

The money is smaller. The final NOFO says "NIMH intends to commit up to $10M to fund at least 1 award in FY27 and in FY28" and "NIDA intends to commit up to $2M to fund 1 award in FY27." The Grants.gov synopsis lists estimated total funding of $12,000,000 across three anticipated awards. There is no award ceiling, no floor, and no cost sharing. Budgets "should reflect the actual needs of the proposed project."

The calendar moved. November 13 is gone. There are now two receipt dates:

Submissions open December 5, 2026, are due by 5:00 p.m. local time, and the NOFO expires June 11, 2027. There is no letter of intent. NIMH plans an optional technical assistance webinar on Microsoft Teams roughly three weeks after posting, which puts it in early December.

The structure is explicit. The forecast described a network. The NOFO specifies how it must be built, staged, and governed, with milestones that determine whether the project continues past year two.

The reading for most applicants: the FY2027 money is meant for one network-anchoring award plus a NIDA-funded piece, and the FY2028 commitment is the second shot. A team that cannot assemble a credible multi-site network by January 5 is not locked out; it has until June 10, and an unsuccessful January applicant can resubmit in June.

The Scientific Question

The NOFO defines RAPIDs as drugs producing "clinically meaningful symptom reduction on a timescale of hours to days." It names exactly three: ketamine and esketamine, which are FDA-approved, and psilocybin and MDMA, described as "emerging late-stage investigational treatments." It states plainly that "esketamine is currently the only FDA-approved RAPID for mental illness."

Notably absent are the neurosteroids brexanolone and zuranolone, approved for postpartum depression and arguably rapid-acting. They do not appear in the text. An applicant who wants to include them should frame them under the NOFO's requirement that the network be able "to pivot to new treatments" as they are approved, and should not build the core protocol around them.

The point of the network is not to prove these drugs work. That is what the sponsors' Phase 3 trials are for. NIMH wants "actionable, real-world evidence to guide the safe and effective implementation of RAPIDs in routine clinical practice." The NOFO lists the evidence packages it expects the network to produce:

• Episode-based or bundled care models
• How much monitoring time is actually required
• Workforce models, including staffing ratios and training
• How often patients need retreatment
• Whether adjunctive psychosocial treatment is necessary
• Downstream cost effects, such as fewer hospitalizations, ED visits, and crisis contacts

Every item on that list is a question payers and health systems are asking right now about Spravato, whose REMS still requires on-site monitoring of at least two hours after each dose. If psilocybin is approved with a session lasting most of a working day, the same questions get larger. NIMH is trying to have the answers in hand when that happens.

The NOFO is equally blunt about what it will not fund. "Traditional explanatory or highly controlled efficacy trials" and projects that are "solely basic neuroscience or preclinical animal models" are non-responsive and will not be reviewed. The program is "intended only for large-scale, coordinated network projects that could not be achieved using other, more standard grant mechanisms."

How the Network Must Be Built

The RAPIDs-CTN has two components. A Data Coordinating Center runs governance, central safety monitoring, data systems, and the unified protocols. Federated Clinical Sites enroll patients in real-world settings: inpatient units, emergency departments, VA facilities, community mental health centers, and specialty clinics.

The award runs up to five years in two milestone-gated stages.

Stage 1 (Years 1–2) stands up the network and runs pilots. Year 1 milestones include a functioning DCC and governance structure, onboarded initial sites with community engagement workflows, standardized NIMH Common Data Elements and safety pipelines, finalized protocols, and launched pilot studies. Year 2 delivers pilot findings on safety, feasibility, utilization, and cost, plus a Stage 2 scale-up plan and an evidence-package plan.

Stage 2 (Years 3–5) runs full-scale pragmatic trials, adds sites, brings in newly approved drugs, and deposits data in the NIMH Data Archive.

NIH program staff use the year-two deliverables to decide whether the project moves to Stage 2. That is the clause that makes this a cooperative agreement in more than name. An NIMH Project Scientist sits on the Steering Committee as a voting member (NIH gets one vote total), the Program Official negotiates final milestones before award, and NIH helps decide which new drugs or treatment arms get added. An independent Data and Safety Monitoring Board oversees safety.

What the Application Must Contain

The Research Strategy is capped at 20 pages, and the Approach must be organized into four labeled subsections: Network Infrastructure and Governance; Unified Protocol and Pragmatic Trial Execution; Data Management and Common Data Elements; and Timeline and Milestones. Use those headings verbatim. Reviewers will be scoring against them.

Two attachments are mandatory, and missing either one makes the application incomplete: a file named "Common Data Elements Applicability.pdf" and one named "Clinical Protocol Schedule of Events.pdf." Treat the filenames as exact.

Letters of collaboration from every clinical site are required, and each must confirm that the site will join the network, follow the unified protocols, and share data through the DCC. Generic letters of enthusiasm will not satisfy that language. NIH also encourages letters documenting leveraged resources, such as in-kind drug supply, EHR data feeds, state registries, or industry and philanthropic support.

The recommended effort levels are high and reviewers are told to check them:

• Contact PD/PI: at least 2.4 person-months (20 percent) per year for all five years
• DCC Director: at least 2.4 person-months
• Each additional multi-PI: at least 1.8 person-months
• Clinical site leads: at least 1.2 person-months

Budget for a two-day, in-person network meeting in the Washington, D.C. area in Year 1. The Approach must address concomitant medication management and protocols for individualized antidepressant tapering or washout, a practical problem in psilocybin trials that many real-world patients will bring with them. Biosketches should highlight experience with multi-site pragmatic or adaptive platform trials.

One inconsistency is worth flagging. The NOFO requires a Data Management and Sharing Plan using NIMH CDEs, NDA deposition with GUIDs, and electronic data capture, but Section VI.3 also says a DMS Plan "is not applicable for this NOFO." That reads like boilerplate left over from another template. Submit a full DMS Plan and confirm with program staff.

Policy Terms Applicants Should Read Twice

Several conditions reflect current HHS policy rather than the science, and they can disqualify an otherwise strong team.

Applications involving substance use "must not support harm reduction." For a network that will treat patients with co-occurring substance use disorders, and that NIDA is co-funding, protocols need to be written in treatment language rather than harm-reduction language. Medication for opioid use disorder, if included, must support comprehensive care models rather than medication-only models. The standard 2026 HHS civil rights certification language also applies.

Foreign organizations and foreign components are not allowed. Every other U.S. organization type is eligible, including universities, nonprofits, for-profit companies and small businesses, state, local, and tribal governments, and federal agencies. An organization may submit more than one application if each is scientifically distinct. Requests to reconsider peer review will not be accepted.

Where This Fits

RAPIDs is the second NIMH-NIDA psychedelic-adjacent opportunity this fall. Its sibling, RFA-MH-27-135, is an R01 on trial-methods problems such as blinding integrity, functional unblinding, and expectancy bias, with about $5.5 million for five or six awards. It closed in October. Neither NOFO mentions the April executive order or the ARPA-H EVIDENT program, but together they mark a deliberate division of labor. ARPA-H and the sponsors push toward approval; FDA finalized its guidance on psychedelic clinical investigations in July; and NIMH is building the infrastructure to study what happens afterward.

That positioning is also the strategic argument for applying. A real-world effectiveness network funded now will be the obvious home for post-approval questions about psilocybin, and potentially MDMA, whose resubmitted PTSD application is pending. The NOFO's language about adding newly approved drugs and sites in Stage 2 invites exactly that expansion.

Who Should Apply, and How

The competitive applicant is not a single academic medical center. It is a coalition that already runs pragmatic or platform trials, has a data coordinating group with NIMH CDE and NDA experience, and can bring sites that look like routine care: a county emergency department, a VA medical center, a community mental health center that already administers Spravato. Generalizability is an explicit review criterion, so a network made entirely of academic psychiatry clinics will score poorly on Environment.

For a January 5 submission, the work for the next seven weeks is mostly not writing:

1. Lock the sites now. Site letters with the required commitments take institutional signatures. Start in November.
2. Decide the comparator. Reviewers score rigor against standard-of-care or active comparators. Pick one and justify it.
3. Write the Stage 1 milestones as numbers. Sites onboarded, participants enrolled in pilots, data-completeness thresholds. The review criteria ask whether milestones are quantifiable.
4. Plan the drug supply. Esketamine is commercially available; psilocybin and MDMA are not. Explain how the network will run arms for investigational drugs before and after approval, including DEA Schedule I registrations where needed.
5. Attend the December webinar and email NIMHRAPIDS@nih.gov with any design questions. For NIDA-relevant components, contact NIDADTMCprogram@mail.nih.gov.

Teams that are not ready by January should treat June 10 as the realistic target and use the January cycle's outcome to read what NIMH funded. With only $12 million on the table and one network anchoring the field for five years, the award will shape how rapid-acting psychiatric drugs are delivered in routine care for the rest of the decade. A partial network submitted early is a worse bet than a complete one submitted in June.